[wpml_language_selector_widget]

Evaluating the Burden, Pathophysiology, and Comorbidities Associated with Idiopathic Hypersomnia to Inform Diagnosis and Treatment

PROGRAM CHAIR

Michael J. Thorpy, MD
Professor of Neurology
Albert Einstein College of Medicine
Bronx, NY

FACULTY PRESENTER

Nancy Foldvary-Schaefer, DO, MS
Professor of Neurology
Cleveland Clinic Lerner College of Medicine
Cleveland Clinic Sleep Disorders Center
Cleveland, OH

PROGRAM OVERVIEW

This educational program will discuss the burden of idiopathic hypersomnia (IH), assess mechanisms that address underlying pathology of the disease, and analyze available clinical data that look at the effect of treatment on sleep habits, quality of life, and cardiovascular risk. The program will also use guidelines and cases to describe best practices in patient counseling to ensure effective use of approved therapy for IH.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of sleep specialists, psychiatrists, neurologists, pulmonologists, and allied healthcare professionals who treat patients with or who are at risk for idiopathic hypersomnia.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Summarize the burden of idiopathic hypersomnia, including the burden of elevated cardiovascular risk and comorbidities
  • Evaluate the underlying pathology of idiopathic hypersomnia and mechanisms to address underlying pathology
  • Analyze available clinical data regarding the effect of treatment on sleep rating scales, quality of life, cardiovascular risk, and cognitive function
  • Review best practices in patient counseling to ensure effective use of approved therapy for idiopathic hypersomnia

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

Faculty Member Disclosures
Michael J. Thorpy, MD Advisory Board/Consultant Fees: Alkermes, Avadel Pharmaceuticals, Axsome Therapeutics, Centessa Pharmaceuticals, Eisai Inc., Harmony Biosciences, Idorsia Pharmaceuticals
Nancy Foldvary-Schaefer, DO, MS Royalties: Oxford University Press, UpToDate
Contracted Research: Harmony Biosciences, Jazz Pharmaceuticals, Takeda Pharmaceuticals, Suven Life Sciences

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Arpan Patel, MD, has nothing to disclose.
  • Michael Milano, MD, has received royalties from Wolters Kluwer (Up ToDate author royalties).
  • Brianna Hefele, RN, has nothing to disclose.
  • A medical reviewer from CME Peer Review LLC has nothing to disclose.
  • Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
  • Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
  • Russie Allen, MS, Accreditation and Outcomes Manager, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASED DATE: October 18, 2024
EXPIRATION DATE: October 18, 2025

Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Pin It on Pinterest

Scroll to Top

You are now leaving the THRIVE site

The THRIVE Neuroscience Community of Care site is funded by an independent medical education grant from Jazz Pharmaceuticals. The following site is not affiliated with the THRIVE educational initiative and MLG is not responsible for its content.

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers